Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

NetraMark Holdings Inc C.AIAI

Alternate Symbol(s):  AINMF

NetraMark Holdings Inc. is a Canada-based company, which is focused on the development of Generative Artificial Intelligence (Gen AI)/Machine Learning (ML) solutions targeted at the pharmaceutical industry. The Company’s product offering uses a novel topology-based algorithm that has the ability to parse patient data sets into subsets of people that are strongly related according to several variables simultaneously. This allows the Company to use a variety of ML methods, depending on the character and size of the data, to transform the data into powerfully intelligent data that activates traditional AI/ML methods. The result is that it can work with smaller datasets and accurately segment diseases into different types, as well as accurately classify patients for sensitivity to drugs and/or efficacy of treatment. The typical molecular data used is RNASeq, microarray, single nucleotide polymorphism (SNP) and methylation.


CSE:AIAI - Post by User

Post by Justdosomeddon Nov 09, 2021 4:08pm
107 Views
Post# 34106628

News Release/Quick Overview

News Release/Quick Overview
Nuresene announced that Dr. Joseph Geraci ($MEND’s CSO and co-founder of NetraMark) would present research on ALS at the EndALS Pitch Day hosted by Kaggle, a data science subsidiary of Google. “Dr. Geraci helped judge the winning solutions over the past few days and supported Kaggle to discover a set of new drug targets and repurposing candidates, leveraging NetraMark's AI solutions to identify unique features that distinguished different aspects of ALS. NetraMark has been invited to present novel research at the EndALS Kaggle Pitch Day, alongside the competition winners.”
 
https://ca.finance.yahoo.com/news/nurosenes-chief-scientific-officer-dr-140000367.html
 
So what is Nurosene?
 
- They’re a company focused on mental health and wellness, combining movement, brain, nutrition, and recovery with technology to help improve health for users. (The 4x4 model)
 
- Their app, Nuro, leverages machine learning and cutting edge research to assist those struggling with mental health or looking to create better habits
 
- Netramark (a wholly owned subsidiary) is another driver for the business. The AI is used by companies all over the pharma development stages, helping boost efficiency and effectiveness of research and development
 
$MEND is also Purpose Investments top holding in the small cap fund managed by Bruce Campbell. (4.55% of the Canadian Equity Growth Fund). And with $56 AUM, the 4.55% is worth around $2.55M or just about 4.5% of $MEND.
 
Credits to Allstreets for this one: https://twitter.com/allstreetswolf/status/1458138629339959298?s=21
 
Considering future potential and what they’ve already been able to accomplish, the current market cap of $57M is fairly undervalued. I’ll be keeping a close eye on $MEND. Also, just listened to an interesting podcast with Dr. Garaci. He goes over his life story, and $MEND, worth a listen.
 
https://open.spotify.com/episode/1z1ZgOPIQEYr0mtt60dT82?si=fuXvpdkDRvqkG76AbCCdaQ
<< Previous
Bullboard Posts
Next >>